Global law firm White & Case LLP has advised IK Partners on its sale of Mabtech to EQT Healthcare Growth Strategy.
IK Partners is a pan-European private equity firm focused on investments in Benelux, DACH, France, Nordics and the UK. Since 1989 it has raised more than €14 billion of capital and invested in 180 European companies.
Mabtech is a biotech company founded in Sweden in 1986 that develops immunoassays for life science research. Its products are used by researchers and companies worldwide to study immune responses, including cases of cancer, allergies and infectious diseases, and to monitor vaccine trials.
The White & Case team which advised on the transaction was led by partner Shoan Panahi (Stockholm) and included partners Johan Thiman, Carl Hugo Parment (both Stockholm) and Mikko Hulkko (Helsinki), and associates Sebastian Wallin, Anders Westling, Karl Nordlin, Even Nordsletten, Filip Karlsson, Tea Lasu, Mana Sohrabi, Isak Bruncevic, Josefine Bågholt, Gustaf Wiklund, Izabella Barisa, Alexander Hase, Alexander Berlin-Jarhamn, Carl Runesson, Siavash Saberian (all Stockholm) Thomas Killeen, Asmo Esser (both Helsinki) and Joar Lindén (Brussels).
Press contact
For more information please speak to your local media contact.
Read the orginal article: https://www.whitecase.com/news/press-release/white-case-advises-ik-partners-sale-mabtech-eqt-healthcare-growth-strategy